**
A new clinical trial assessing the safety and effectiveness of puberty-blocking medications for children questioning their gender identity is set to commence in the UK, with participants required to be at least 11 years old. The Pathways Trial, which faced a pause in February 2026 due to safety concerns raised by the Medicines and Healthcare products Regulatory Agency (MHRA), has established a minimum age for participation after extensive discussions aimed at reinforcing the trial’s safeguards.
Trial Resumption and Age Criteria
The Pathways Trial will begin recruiting participants in August 2026, although legal challenges from some clinicians and advocacy groups could potentially delay the process. The MHRA initially recommended raising the minimum age for participants to 14—a significant shift given that no age limit had been previously established. As a result of these deliberations, the trial has now set the age for birth-registered female participants at 11 and for birth-registered males at 12.
This trial aims to explore the impacts of puberty blockers—medications that delay or inhibit the onset of puberty—on the physical, emotional, and social well-being of children under 16 who are currently receiving gender identity services. Researchers from King’s College London have committed to not enrolling participants until at least August 1 to allow adequate time for any ongoing legal proceedings to unfold. Importantly, any child wishing to participate must secure parental consent and demonstrate a clear understanding of the potential risks and benefits associated with the treatment.
Safety and Ethical Concerns
The decision to reinstate the trial comes amidst a backdrop of intense scrutiny regarding the ethics and safety of administering puberty blockers to minors. In 2024, the use of these medications for under-18s was banned following a comprehensive review by Dr Hilary Cass, which indicated that the foundations of gender medicine were “shaky,” particularly concerning the evidence supporting treatment protocols.
In light of these concerns, the research team has pledged to enhance patient information and clarify guidelines regarding the use of puberty blockers. There will now be explicit protocols for when to cease treatment, especially if adverse effects such as bone density loss or abnormal vaginal bleeding arise. Moreover, detailed information regarding fertility preservation will be made available to participants and their families.
Ongoing Legal Challenges and Public Debate
The trial has ignited a fierce debate among medical professionals, legal experts, and advocacy groups. Some medical practitioners have expressed doubts about the necessity of the trial, while campaigners have initiated legal action against the MHRA and other stakeholders. They argue that the trial is unethical and that children may not be fully capable of providing informed consent for treatments that could have long-term implications for their health and fertility.
Professor Sir Jonathan Montgomery, a prominent figure in health care law at University College London, acknowledges the importance of the legal proceedings, stating that they could shed light on any regulatory oversights. He emphasised the need for clarity to protect the interests of all parties involved.
A spokesperson for the LGBTQ+ charity Stonewall has expressed cautious optimism regarding the trial’s revised protocol, noting that many young individuals have been left in a state of uncertainty since the ban on puberty blockers. The spokesperson highlighted the emotional and physical distress faced by these young people and the imperative to avoid prolonging their suffering.
Why it Matters
The Pathways Trial represents a critical juncture in the ongoing discourse surrounding gender identity treatment for minors. As the trial moves forward amidst legal and ethical challenges, its outcomes could significantly influence future policies and practices in gender healthcare. The implications for the well-being of young people navigating gender dysphoria are profound, as the trial aims to provide much-needed evidence on the safety and efficacy of puberty blockers. The debate surrounding consent, safety, and the rights of young individuals in healthcare settings underscores the urgency of establishing a compassionate and scientifically informed approach to gender identity treatments.